MR-Linacs enable daily functional imaging to be performed in patients being treated with radiotherapy. In this work, the diffusion sequence developed by the MRL Consortium biomarkers working group underwent technical validation, showing accurate and repeatable phantom ADC measurements. Daily, whole-prostate ADC mapping was also performed in patients undergoing treatment for prostate cancer on an MRL. No significant differences were observed in whole-prostate ADC during the course of treatment for conventional and stereotactic ablative body radiotherapy (SABR) treatments. Absence of significant change in ADC could be related to the fact that patients were treated with neo-adjuvant hormone therapy prior to radiotherapy.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords